3
|
Todica A, Beetz NL, Günther L, Zacherl MJ, Grabmaier U, Huber B, Bartenstein P, Brunner S, Lehner S. Monitoring of Cardiac Remodeling in a Mouse Model of Pressure-Overload Left Ventricular Hypertrophy with [ 18F]FDG MicroPET. Mol Imaging Biol 2019; 20:268-274. [PMID: 28852941 DOI: 10.1007/s11307-017-1114-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
PURPOSE This study aims to analyze the left ventricular function parameters, scar load, and hypertrophy in a mouse model of pressure-overload left ventricular (LV) hypertrophy over the course of 8 weeks using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) micro-positron emission tomography (microPET) imaging. PROCEDURES LV hypertrophy was induced in C57BL/6 mice by transverse aortic constriction (TAC). Myocardial hypertrophy developed after 2-4 weeks. ECG-gated microPET scans with [18F]FDG were performed 4 and 8 weeks after surgery. The extent of fibrosis was measured by histopathologic analysis. LV function parameters and scar load were calculated using QGS®/QPS®. LV metabolic volume (LVMV) and percentage injected dose per gram were estimated by threshold-based analysis. RESULTS The fibrotic tissue volume increased significantly from 4 to 8 weeks after TAC (1.67 vs. 3.91 mm3; P = 0.044). There was a significant increase of the EDV (4 weeks: 54 ± 15 μl, 8 weeks: 79 ± 32 μl, P < 0.01) and LVMV (4 weeks: 222 ± 24 μl, 8 weeks: 276 ± 52 μl, P < 0.01) as well as a significant decrease of the LVEF (4 weeks: 56 ± 17 %, 8 weeks: 44 ± 20 %, P < 0.01). The increase of LVMV had a high predictive value regarding the amount of ex vivo measured fibrotic tissue (R = 0.905, P < 0.001). The myocardial metabolic defects increased within 4 weeks (P = 0.055) but only moderately correlated with the fibrosis volume (R = 0.502, P = 0.021). The increase in end-diastolic volume showed a positive correlation with the fibrosis at 8 weeks (R = 0.763, P = 0.017). CONCLUSIONS [18F]FDG-PET is applicable for serial in vivo monitoring of the TAC mouse model. Myocardial hypertrophy, the dilation of the left ventricle, and the decrease in LVEF could be reliably quantified over time, as well as the developing localized scar. The increase in volume over time is predictive of a high fibrosis load.
Collapse
Affiliation(s)
- Andrei Todica
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
| | - Nick L Beetz
- Medical Department I-Cardiology, University Hospital, LMU Munich, Munich, Germany
| | - Lisa Günther
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - Mathias J Zacherl
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - Ulrich Grabmaier
- Medical Department I-Cardiology, University Hospital, LMU Munich, Munich, Germany
| | - Bruno Huber
- Medical Department I-Cardiology, University Hospital, LMU Munich, Munich, Germany
| | - Peter Bartenstein
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - Stefan Brunner
- Medical Department I-Cardiology, University Hospital, LMU Munich, Munich, Germany
| | - Sebastian Lehner
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.,Ambulatory Healthcare Center Dr. Neumaier & Colleagues, Radiology, Nuclear Medicine, Radiation Therapy, Regensburg, Germany
| |
Collapse
|
6
|
Verma SK, Garikipati VNS, Krishnamurthy P, Schumacher SM, Grisanti LA, Cimini M, Cheng Z, Khan M, Yue Y, Benedict C, Truongcao MM, Rabinowitz JE, Goukassian DA, Tilley D, Koch WJ, Kishore R. Interleukin-10 Inhibits Bone Marrow Fibroblast Progenitor Cell-Mediated Cardiac Fibrosis in Pressure-Overloaded Myocardium. Circulation 2017; 136:940-953. [PMID: 28667100 DOI: 10.1161/circulationaha.117.027889] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2017] [Accepted: 06/15/2017] [Indexed: 12/21/2022]
Abstract
BACKGROUND Activated fibroblasts (myofibroblasts) play a critical role in cardiac fibrosis; however, their origin in the diseased heart remains unclear, warranting further investigation. Recent studies suggest the contribution of bone marrow fibroblast progenitor cells (BM-FPCs) in pressure overload-induced cardiac fibrosis. We have previously shown that interleukin-10 (IL10) suppresses pressure overload-induced cardiac fibrosis; however, the role of IL10 in inhibition of BM-FPC-mediated cardiac fibrosis is not known. We hypothesized that IL10 inhibits pressure overload-induced homing of BM-FPCs to the heart and their transdifferentiation to myofibroblasts and thus attenuates cardiac fibrosis. METHODS Pressure overload was induced in wild-type (WT) and IL10 knockout (IL10KO) mice by transverse aortic constriction. To determine the bone marrow origin, chimeric mice were created with enhanced green fluorescent protein WT mice marrow to the IL10KO mice. For mechanistic studies, FPCs were isolated from mouse bone marrow. RESULTS Pressure overload enhanced BM-FPC mobilization and homing in IL10KO mice compared with WT mice. Furthermore, WT bone marrow (from enhanced green fluorescent protein mice) transplantation in bone marrow-depleted IL10KO mice (IL10KO chimeric mice) reduced transverse aortic constriction-induced BM-FPC mobilization compared with IL10KO mice. Green fluorescent protein costaining with α-smooth muscle actin or collagen 1α in left ventricular tissue sections of IL10KO chimeric mice suggests that myofibroblasts were derived from bone marrow after transverse aortic constriction. Finally, WT bone marrow transplantation in IL10KO mice inhibited transverse aortic constriction-induced cardiac fibrosis and improved heart function. At the molecular level, IL10 treatment significantly inhibited transforming growth factor-β-induced transdifferentiation and fibrotic signaling in WT BM-FPCs in vitro. Furthermore, fibrosis-associated microRNA (miRNA) expression was highly upregulated in IL10KO-FPCs compared with WT-FPCs. Polymerase chain reaction-based selective miRNA analysis revealed that transforming growth factor-β-induced enhanced expression of fibrosis-associated miRNAs (miRNA-21, -145, and -208) was significantly inhibited by IL10. Restoration of miRNA-21 levels suppressed the IL10 effects on transforming growth factor-β-induced fibrotic signaling in BM-FPCs. CONCLUSIONS Our findings suggest that IL10 inhibits BM-FPC homing and transdifferentiation to myofibroblasts in pressure-overloaded myocardium. Mechanistically, we show for the first time that IL10 suppresses Smad-miRNA-21-mediated activation of BM-FPCs and thus modulates cardiac fibrosis.
Collapse
Affiliation(s)
- Suresh K Verma
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Venkata N S Garikipati
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Prasanna Krishnamurthy
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Sarah M Schumacher
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Laurel A Grisanti
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Maria Cimini
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Zhongjian Cheng
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Mohsin Khan
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Yujia Yue
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Cindy Benedict
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - May M Truongcao
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Joseph E Rabinowitz
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - David A Goukassian
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Douglas Tilley
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Walter J Koch
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.)
| | - Raj Kishore
- From Center for Translational Medicine (S.K.V., V.N.S.G., S.M.S., L.A.G., M.C., Z.C., M.K., Y.Y., C.B., M.M.T., J.E.R., D.A.G., D.T., W.J.K., R.K.) and Department of Pharmacology (D.T., W.J.K., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; and Department of Biomedical Engineering, School of Medicine, University of Alabama at Birmingham (P.K.).
| |
Collapse
|
10
|
Daltro PS, Alves PS, Castro MF, Azevedo CM, Vasconcelos JF, Allahdadi KJ, de Freitas LAR, de Freitas Souza BS, Dos Santos RR, Soares MBP, Macambira SG. Administration of granulocyte-colony stimulating factor accompanied with a balanced diet improves cardiac function alterations induced by high fat diet in mice. BMC Cardiovasc Disord 2015; 15:162. [PMID: 26631050 PMCID: PMC4668667 DOI: 10.1186/s12872-015-0154-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 11/19/2015] [Indexed: 11/10/2022] Open
Abstract
Background/Objectives High fat diet (HFD) is a major contributor to the development of obesity and cardiovascular diseases due to the induction of cardiac structural and hemodynamic abnormalities. We used a model of diabetic cardiomyopathy in C57Bl/6 mice fed with a HFD to investigate the effects of granulocyte-colony stimulating factor (G-CSF), a cytokine known for its beneficial effects in the heart, on cardiac anatomical and functional abnormalities associated with obesity and type 2 diabetes. Methods Groups of C57Bl/6 mice were fed with standard diet (n = 8) or HFD (n = 16). After 36 weeks, HFD animals were divided into a group treated with G-CSF + standard diet (n = 8) and a vehicle control group + standard diet (n = 8). Cardiac structure and function were assessed by electrocardiography, echocardiography and treadmill tests, in addition to the evaluation of body weight, fasting glicemia, insulin and glucose tolerance at different time points. Histological analyses were performed in the heart tissue. Results HFD consumption induced metabolic alterations characteristic of type 2 diabetes and obesity, as well as cardiac fibrosis and reduced exercise capacity. Upon returning to a standard diet, obese mice body weight returned to non-obese levels. G-CSF administration accelerated the reduction in of body weight in obese mice. Additionally, G-CSF treatment reduced insulin levels, diminished heart fibrosis, increased exercise capacity and reversed cardiac alterations, including bradycardia, elevated QRS amplitude, augmented P amplitude, increased septal wall thickness, left ventricular posterior thickening and cardiac output reduction. Conclusion Our results indicate that G-CSF administration caused beneficial effects on obesity-associated cardiac impairment.
Collapse
Affiliation(s)
- Pâmela Santana Daltro
- Center for Biotechnology and Cell Therapy, Hospital Sao Rafael, Salvador, BA, Brazil.
| | - Paula Santana Alves
- Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPqGM/FIOCRUZ), Salvador, BA, Brazil.
| | | | - Carine M Azevedo
- Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPqGM/FIOCRUZ), Salvador, BA, Brazil.
| | | | - Kyan James Allahdadi
- Center for Biotechnology and Cell Therapy, Hospital Sao Rafael, Salvador, BA, Brazil.
| | - Luiz Antônio Rodrigues de Freitas
- Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPqGM/FIOCRUZ), Salvador, BA, Brazil. .,Federal University of Bahia, Salvador, BA, Brazil.
| | - Bruno Solano de Freitas Souza
- Center for Biotechnology and Cell Therapy, Hospital Sao Rafael, Salvador, BA, Brazil. .,Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPqGM/FIOCRUZ), Salvador, BA, Brazil.
| | | | - Milena Botelho Pereira Soares
- Center for Biotechnology and Cell Therapy, Hospital Sao Rafael, Salvador, BA, Brazil. .,Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPqGM/FIOCRUZ), Salvador, BA, Brazil.
| | - Simone Garcia Macambira
- Center for Biotechnology and Cell Therapy, Hospital Sao Rafael, Salvador, BA, Brazil. .,Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPqGM/FIOCRUZ), Salvador, BA, Brazil. .,Federal University of Bahia, Salvador, BA, Brazil.
| |
Collapse
|